C. Aul
- Hematology top 2%
- Acute Myeloid Leukemia Research 16
- Multiple Myeloma Research and Treatments 6
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 4
- Myeloproliferative Neoplasms: Diagnosis and Treatment 3
- Emergency Medicine top 10%
- Orthopedics and Sports Medicine top 10%
-
- Metabolism and Genetic Disorders 3
-
- Neutropenia and Cancer Infections 3
-
- Retinoids in leukemia and cellular processes 3
- Porphyrin Metabolism and Disorders 2
- Co-authors
- Norbert GattermannWolfgang SchneiderUlrich GermingA. HeyllG. DerigsVolker RundeD. SöhngenW Schneider
- Cited by
- HematologyGeneticsEmergency Medicine
- Partner nations
- GermanyUnited StatesBelgium
In The Last Decade
C. Aul
33 papers receiving 702 citations
Peers
Comparison fields: 5 of 63
- Hematology 519
- Genetics 250
- Emergency Medicine 87
- Orthopedics and Sports Medicine 45
- Pulmonary and Respiratory Medicine 109
Countries citing papers authored by C. Aul
This map shows the geographic impact of C. Aul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Aul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Aul more than expected).
Fields of papers citing papers by C. Aul
This network shows the impact of papers produced by C. Aul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Aul. The network helps show where C. Aul may publish in the future.
Co-authorship network
The 25 scholars most cited alongside C. Aul, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 16 | |
| 2 | 2009 | 0 | |
| 3 | 2008 | 1 | |
| 4 | 2008 | 0 | |
| 5 | 2008 | 0 | |
| 6 | 2007 | 44 | |
| 7 | 2004 | 1 | |
| 8 | T-PLL-1 protocol of the German CLL study group (GCLLSG) - a prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation as first-line treatment in T-PLL. | 2003 | 6 |
| 9 | 2002 | 26 | |
| 10 | 2002 | 45 | |
| 11 | 2000 | 1 | |
| 12 | Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients. | 1997 | 7 |
| 13 | 1997 | 16 | |
| 14 | Levels of circulating endothelial adhesion molecules (sE-selectin and sVCAM-1) in adult patients with acute leukemia. | 1996 | 20 |
| 15 | 1993 | 44 | |
| 16 | 1992 | 4 | |
| 17 | Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. | 1992 | 210 |
| 18 | 1991 | 13 | |
| 19 | 1990 | 9 | |
| 20 | [Effect of valve type and valve function on chronic intravascular hemolysis after alloprosthetic mitral and aortic valve replacement]. | 1983 | 13 |
About C. Aul
C. Aul is a scholar working on Hematology, Genetics and Clinical Biochemistry, having authored 37 papers that have together received 722 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (16 papers), Multiple Myeloma Research and Treatments (6 papers), Chronic Lymphocytic Leukemia Research (4 papers), Metabolism and Genetic Disorders (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), Neutropenia and Cancer Infections (3 papers), Retinoids in leukemia and cellular processes (3 papers) and Porphyrin Metabolism and Disorders (2 papers). The work is most often cited by research in Hematology (519 citations), Genetics (250 citations) and Emergency Medicine (87 citations). C. Aul has collaborated with scholars based in Germany, United States and Belgium. Frequent co-authors include Norbert Gattermann, Wolfgang Schneider, Ulrich Germing, A. Heyll, G. Derigs, Volker Runde, D. Söhngen, W Schneider, Aristoteles Giagounidis and Matthias Leschke. Their work appears in journals such as Leukemia Research, Annals of Hematology, Blood, Oncology Reports and Recent results in cancer research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.